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One-Year Follow-Up of Patients With Refractory Angina
Randomized to Percutaneous Transmyocardial
Revascularization Versus Medical Therapy
EMERSON C. PERIN, MD, FACC
TEXAS HEART INSTITUTE, HOUSTON, TEXAS
Percutaneous transmyocardial revascularization (PTMR)
has previously been reported to be safe and to improve
angina and exercise tolerance. However, controlled compar-
isons with longer follow-up times are needed if PTMR is to
be a viable treatment. Of 325 patients with New York Heart
Association (NYHA) class III–IV angina who were poor
candidates for percutaneous or surgical revascularization,
163 were randomized to undergo PTMR with a fiberoptic
holmium-laser system, and 162 were randomized to receive
solely medical management. Enrolled patients were required
to have a left ventricular ejection fraction of at least 30% and
a myocardial wall thickness of at least 9 mm by echocardi-
ography in the PTMR target region.
Seven percent of the medically managed patients crossed
over to the PTMR group. The six- and 12-month analyses
were performed on an intention-to-treat basis. An average
of 19 myocardial channels per patient in the PTMR group
were created with the laser; their mean hospital length of
stay was 1.8 days. Major adverse events associated with
PTMR developed in 4.3% of cases and included one death,
one Q-wave myocardial infarction (MI), one cerebrovascu-
lar event, and six instances of tamponade.
At 12 months, 37% of the PTMR group and 18% of the
medically managed patients had improved by two or more
NYHA classes (p , 0.001). Fifty-five percent of PTMR-
treated patients and 31% of patients in the medical group
were in NYHA class II or better at 12 months (p , 0.001).
The primary end point of the study was treadmill exercise
tolerance. In the PTMR group, mean time increased from
433 s at baseline to 534 s at 12 months, an improvement of
101 s versus a decrease of 16 s in the medically managed
group. At both the six- and 12-month follow-ups, patients
who had undergone PTMR were able to exercise signifi-
cantly longer compared with baseline than were medically
managed patients (p , 0.001 at six months and p , 0.001
at 12 months). The two groups had statistically similar
12-month rates of death, Q-wave and non–Q-wave MI,
and rehospitalization.
Commentary. As the population ages, an increasing
proportion of patients with coronary artery disease (CAD)
will be found to have few or no options for improving
coronary blood flow through epicardial conduit vessels. The
current study demonstrates that PTMR can be applied
safely in a severely ill population of patients. The findings of
the current study are noteworthy because of their internal
consistency and because of the robust treatment effect
observed in the setting of a randomized trial. For the sake of
comparison, it is worth noting that, in the Angioplasty
Compared to Medicine (ACME) study of patients under-
going single-vessel angioplasty, there was an increase in
exercise time of only 2.1 min for patients (with mild CAD)
undergoing percutaneous transluminal coronary angio-
plasty, compared with those receiving medical therapy only.
By contrast, the current study does not close the book on
PTMR. It must be remembered that, although the current
study is randomized, it is not blinded—a limitation that
becomes particularly important when evaluating subjective
end points such as exercise time and anginal class. However,
the consistency of the findings within this study strongly
suggests that further investigation of PTMR is indicated
and that modifications of the technique, perhaps in combi-
nation with endocardial mapping or with angiogenic growth
factors, or using alternative forms of energy. In addition, the
statistical issues with missing values are complex, and not
enough cardiac events occurred in either the intervention or
control populations to ensure the safety of the procedure for
broad populations over the long term.
Phase II, Multicenter, Double-Blind, Placebo-Controlled,
Dose-Finding Study for Safety, Pharmacokinetics, and
Efficacy of Recombinant Fibroblast Growth Factor (rFGF-2)
in Subjects With Coronary Artery Disease (CAD): FGF-2
Initiating Revascularization Support Trial (FIRST)
MICHAEL SIMONS, MD, FACC
BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON,
MASSACHUSETTS
A phase I clinical trial preliminarily suggested that an
intracoronary (IC) 36 mg/kg infusion of rFGF-2, a heparin-
binding growth factor that may induce angiogenesis, im-
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proved indirect measures of myocardial ischemia in patients
with CAD. In a phase II safety, pharmacokinetic, and
efficacy study, 337 patients with CAD who were poor
candidates for surgical or percutaneous revascularization
were randomized to receive IC rFGF-2 at one of three
dosages, or placebo. The patients were required to have a
left ventricular ejection fraction .30% and reversible myo-
cardial perfusion defects at exercise thallium/sestamibi scin-
tigraphy.
Patients received two 10-min infusions of 10 mL of active
therapy or placebo in two vessels supplying the largest viable
myocardial vascular beds observed at perfusion imaging.
Active therapy was administered to 82 patients at 0.3 mg/kg,
to 84 patients at 3.0 mg/kg, and to 85 patients at
30.0 mg/kg; 86 patients received placebo. The mean change
in treadmill exercise time from baseline to 90 days, the
primary efficacy end point, was 65 s for patients receiving
rFGF-2 and 45 s for patients receiving placebo (p 5 0.64).
However, among patients older than the median age of 63
years, the mean changes in exercise time were 80 s and 41 s,
respectively (p 5 0.025). No significant differences between
actively treated patients and controls were observed at 90
days in other exercise-test variables or in mean stress, rest
perfusion, or reversibility scores at exercise perfusion imag-
ing. Patients who received rFGF-2 had significantly re-
duced angina frequency at 90 days (a prospectively defined
secondary end point) as determined by the Seattle Angina
Questionnaire (p 5 0.057). Infusions of rFGF-2 appeared
to be safe. Post-hoc analysis suggested that patients who
were older, were more symptomatic, and had greater levels
of myocardial ischemia at baseline tended to gain more
benefit from rFGF-2 than did other actively treated pa-
tients.
Commentary. It is notable that two of the large trials
presented in this session examined novel therapies for
treatment of patients with end-stage CAD and refractory
symptoms. A good deal of attention has been focused on
angiogenic growth factors. Although much is known about
experimental models of angiogenesis, little is known about
its clinical application. Do atherosclerotic human vessels
behave similarly to those of nonatherosclerotic pigs? Is it
more reasonable to divide a dose of a growth factor among
different areas of the coronary circulation or to target a
single coronary artery? Is it more rational to administer a
growth factor into a vessel that should supply collaterals or
into one that should receive them? What is the clinical
importance of collateral vessels in a patient whose epicardial
vessels are too diseased to deliver blood to the new circula-
tion? Perhaps an apt comparison is that of Martian explo-
ration—man has been able to send crude spacecraft to the
red planet but is not even close to sending living human
beings.
At 90 days, the improvement in exercise capacity was
similar to that seen in actively treated patients in the
percutaneous transmyocardial revascularization (PTMR)
trial, while placebo-treated patients in this trial had a 45-s
increase in exercise tolerance compared with a 16-s decrease
in the PTMR trial. Why the difference? Perhaps the timing
of the assessment played an important role, or perhaps it was
the ability to blind a pharmacologic but not a device study.
Nonetheless, the current study, like the prior VEGF in
Ischemia for Vascular Angiogenesis (VIVA) trial of vascular
endothelial growth factor, does appear to contain some
signal along with the noise—improvement in anginal class
as measured using a validated instrument, and a greater
effect in patients with more evidence of ischemia. Clearly,
there is much to be learned about growing new blood
vessels; FIRST appears to be an early step in that direction.
Late Clinical and Angiographic Outcomes After Use of
90Sr/ 90Y Beta Radiation for the Treatment of In-Stent
Restenosis: Results From the 90Sr Treatment of Angiographic
Restenosis (START) Trial
JEFFREY J. POPMA, MD, FACC
BRIGHAM & WOMEN’S HOSPITAL, BOSTON, MASSACHU-
SETTS
Vascular brachytherapy using gamma radiation has signifi-
cantly reduced angiographic and clinical recurrence rates
after balloon angioplasty for in-stent restenosis in three
randomized, controlled trials. Brachytherapy using the beta
emitter 90Sr may provide the additional advantages of
shorter treatment times and reduced operator radiation
exposure. In the START trial, 476 patients with in-stent
coronary restenotic lesions ,20 mm in length were ran-
domized to treatment with the Beta-Cath vascular brachy-
therapy system or to a placebo brachytherapy procedure.
The prescribed radiation dose was calculated at 2 mm from
the center of the source, which consisted of an array of 90Sr
pellets. The radiation dosages were 16 Gy for target lesions
with reference-segment diameters 2.7 mm to 3.3 mm and
20 Gy for lesions with reference-segment diameters 3.0 mm
to 4.0 mm. Antiplatelet therapy initially consisted of ticlo-
pidine for 14 days, which was later changed to ticlopidine or
clopidogrel for 60 days.
The active-therapy and placebo groups were similar with
respect to mean reference-segment diameter and target-
lesion length. Only 21% of the patients received a new stent
for treatment of in-stent restenosis. Clinical and angio-
graphic follow-ups were available for 92% and 82% of the
patients, respectively. Angiographic restenosis was defined
as a .50% diameter stenosis at follow-up. Angiographic
eight-month restenosis rates were assessed in several ways:
1) within the stented coronary segment (mean length:
22 cm), the restenosis rates were 42% for the control group
and 14% for the irradiated group (p , 0.001); 2) within
injured vessel segment (mean length: 25 mm), the restenosis
rates were 45% and 18.2%, respectively (p , 0.001); 3)
within the irradiated vessel segment (mean length: 30 mm),
the restenosis rates were 45.9% and 24.4%, respectively (p ,
0.001); and 4) within a prespecified analysis segment that
encompassed 5 mm distal and 5 mm proximal to the
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irradiated segment (mean length: 40 mm), the restenosis
rates were 45.2% and 28.8%, respectively (p 5 0.001).
The rate of target-vessel revascularization at eight
months, the trial’s primary end point, was 24.1% in the
control group and 16% in the irradiated group, representing
a 34% reduction with active therapy (p 5 0.008). The rates
of major adverse cardiac events, which included target-vessel
failure, death, or nonfatal myocardial infarction, were 25.9%
and 18%, respectively (p 5 0.039). After one early case of
in-stent thrombosis in the control group, no further in-
stances were observed in either group over a follow-up
extending to day 271.
Commentary. In-stent restenosis remains a significant
problem in patients who have undergone percutaneous
coronary intervention; conventional and mechanical debulk-
ing treatments have thus far been unrewarding. Although
intracoronary radiation seems quite promising, a debate is
raging over the benefits of gamma versus beta radiation
sources. The START trial, the largest trial to date of a
beta-emitting source, illustrates the benefits and pitfalls of
intracoronary brachytherapy. Beta irradiation led to a mean-
ingful reduction in both angiographic and clinical restenosis,
but the effect was most pronounced directly within the full-
dose irradiated area. Narrowing at the edges of the radiation
zone lessened this benefit; yet restenosis rates incorporating
the edges were still lower than in the control group. Thus,
the START trial serves as both a proof of principle and an
illustration of the challenges that remain. Another impor-
tant contribution of the START trial was the observation
that subacute thrombosis rates, previously reported to be
approximately 10%, became quite low after thienopyridine
therapy was extended from two weeks to two months. This
important observation, coupled with the admonition to
avoid placing a new stent at the time of brachytherapy,
suggests that previously observed rates of late vessel closure
following brachytherapy (approximately 10%) may be im-
proved by prolonged therapy with thienopyridines.
First Clinical Investigation of a Tissue-Factor Inhibitor
Administered During Percutaneous Coronary
Revascularization: A Randomized, Double-Blinded, Dose-
Escalation Trial—Assessing Safety and Efficacy of FFR-
FVIIa in Percutaneous Transluminal Coronary Angioplasty
(ASIS) Trial
A. MICHAEL LINCOFF, MD, FACC
CLEVELAND CLINICAL FOUNDATION, CLEVELAND, OHIO
The use of modified recombinant human activated factor
VII (FFR-FVIIa, “active-site-inhibited 7” or ASIS), which
competitively inhibits the prothrombotic action of native
factor VIIa, was tested in a phase II study as an antithrom-
bin agent for potential use with percutaneous interventions.
A total of 491 patients undergoing elective or urgent
coronary stenting or balloon angioplasty, not for acute
myocardial infarction (MI) or unstable angina, were ran-
domized to receive either: 1) adjuvant heparin only or 2)
adjuvant FFR-FVIIa at one of six escalating dosage levels
with supplemental heparin at gradually diminishing dos-
ages. Seven groups were to receive FFR-FVIIa plus heparin
in varying proportions, with an additional group receiving
heparin (100 U/kg) plus a placebo. The dosage escalation
arms included FFR-FVIIa at 50 m/kg to 400 m/kg and
heparin (with the lowest FFR-FVIIa dosage) at 4,000 U/kg
or (in the other arms) 40 U/kg to 70 U/kg. Dosages of
FFR-FVIIa could be reduced, and heparin dosages in-
creased, at the discretion of the steering committee.
An excess of thrombotic complications with FFR-FVIIa
at the 50 m/kg and 100 m/kg levels, despite co-
administration of heparin, led to accelerated escalation of
the FFR-FVIIa dosage. For the primary end point—a
composite of death, MI, urgent revascularization, abrupt
vessel closure, or bailout using a glycoprotein IIb/IIIa
receptor blocker or heparin by day 7 or by discharge—the
rates were 20% in the control group and 5.5% to 38.9% in
the combined heparin-FFR-FVIIa groups (NS). No differ-
ences were observed in the rates of major or minor bleeding
complications; however, the risk of “insignificant bleeding”
(primarily access-site hematomas) was significantly in-
creased in all FFR-VIIa groups compared with control.
Combined analysis of the 210 patients who received FFR-
VIIa at the highest dosage of 400 m/kg showed a nonsig-
nificant trend toward a reduction in the primary end point
compared with the control group, 21.6% versus 11.9% (p 5
0.073).
Commentary. Heparin is the drug we love to hate.
Unfortunately, our therapeutic armamentarium contains
few agents to interfere with thrombin-mediated clot forma-
tion. A broad variety of new anticoagulants have been
developed to replace heparin. However, with the exception
of the low–molecular-weight derivatives of heparin, success
thus far has been limited to modest success for direct
thrombin antagonists in acute coronary syndromes and
during the first few days after percutaneous coronary inter-
ventions. The ASIS trial represents one of the first attempts
to move “upstream” in the coagulation cascade (i.e., to block
the generation of thrombin rather than its activity). Factor
VIIa complexes with tissue factor, leading penultimately to
the formation of factor Xa and ultimately to the generation
of thrombin. As demonstrated by ASIS, the therapeutic
road upstream is also likely to travel uphill. Although this
dose-finding study was not designed to test the efficacy of
FFR-VIIa regimens, the preliminary findings contain some
disturbing as well as some encouraging information. Ad-
junctive heparin in combination with FFR-VIIa was re-
quired to prevent vascular thrombosis, so the regimens could
not be described as “heparin-sparing.” At low doses of
FFR-VIIa, vascular thrombosis was observed, suggesting
either that there was incomplete blockade of the heparin
generation pathway or that the picomolar quantities of
thrombin that are generated independent of the TF-VIIa
pathway may be sufficient to cause periprocedural ischemia
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in the absence of sufficient blockade of thrombin activity. By
contrast, whatever quantity of thrombin “escaped” the
blockade of TF-VIIa was not sufficient to prevent access-
site bleeding. Although these findings should not by any
means quench the movement to study antagonists of throm-
bin generation, they should indicate that such investigations
need to be undertaken cautiously and that careful measure-
ments of thrombin generation and activity are likely to be
needed as adjuncts while such therapies are being refined.
Intracoronary Stenting or Angioplasty for Restenosis
Reduction in Small Arteries (ISAR-SMART) Trial
ADNAN KASTRATI, MD
DEUTSCHES HERZZENTRUM, MUNICH, GERMANY
Randomized clinical trials that have shown improved out-
comes with coronary stenting compared with balloon an-
gioplasty included target vessels with reference-segment
diameters no smaller than 3 mm. It is unknown whether
rates of restenosis and other outcomes with stents are
superior to those of balloons in arteries with smaller refer-
ence diameters. In general, small-vessel percutaneous inter-
ventions have been associated with increased risk of com-
plications.
In the ISAR-SMART trial, 404 patients with symptom-
atic coronary disease, excluding acute myocardial infarction
(MI), and target coronary lesions amenable to intervention
with reference-segment diameters of 2 mm to 2.8 mm were
randomized to treatment with either stenting or with
balloon angioplasty alone. The 204 stent recipients and 200
patients treated by balloon-only received adjuvant abcix-
imab (bolus plus 12-h infusion) as well as aspirin and
ticlopidine (for four weeks with stents and for two weeks
with balloon-only). The mean target-vessel reference-
segment diameter was 2.4 mm in both groups. Stenting was
performed for intimal dissection in 16.5% of patients in the
balloon-only group. The mean maximal dilation pressure
was significantly higher in the stent group (13.5 atm versus
12.0 atm for balloon-only patients) (p , 0.001). The mean
residual stenosis severity was 7% in the stented group and
18.8% in the balloon-only group (p , 0.001).
Thirty-day rates of death and nonfatal MI were low in
both groups and not significantly different. The rates of
survival free of MI at seven months were 96.6% and 97%,
respectively. Quantitative angiography at six months, avail-
able for 82% of the patients, indicated restenosis rates of
35.7% and 37.5% for stented and balloon-only patients,
respectively, when restenosis was defined as a target-site
recurrent lesion of at least 50% severity. The restenosis rates
were 22.2% and 18.8%, respectively, when restenosis was
defined as a recurrence of at least 70% severity. The
six-month rates of target-lesion revascularization were
20.1% and 16.5%, respectively. None of the differences in
six-month angiographic or clinical measures of restenosis
was significant, suggesting that stenting does not reduce
restenosis rates compared with standard balloon angioplasty
with provisional stenting in small coronary vessels.
Commentary. Despite advances in technical and phar-
macologic aspects of percutaneous coronary intervention,
small coronary arteries continue to pose a challenge for the
interventionalist. Approximately one third of coronary in-
terventions are now performed in vessels ,3.0 mm in
diameter; as the population ages and the incidence of
diabetes increases, this proportion is likely to increase.
Because smaller vessels leave little margin for error, the rates
of both procedural complications and restenosis are higher
in small vessels. The issue of whether or not to place
intracoronary stents in small vessels continues to vex inter-
ventional operators. Two randomized studies presented at
the Annual Scientific Session, BESMART and ISAR-
SMART, have arrived at opposite conclusions on the same
issue. Although the trials are similar in many aspects, several
important differences do exist and may have some bearing
on explaining the trials’ divergent findings. Among these
differences are the differential rates of angiographic
follow-up (81% for ISAR-SMART and 91% for
BE SMART), the differing definition of “restenosis” (70%
for ISAR-SMART and 50% for BESMART), and the
routine use of the glycoprotein IIb/IIIa antagonist abcix-
imab in ISAR-SMART. It is interesting that the propor-
tion of stented patients with recurrent stenoses is very
similar between the two trials; however, it appears that a
substantial number of patients treated with conventional
balloon angioplasty had recurrent stenoses between 50% and
70% of the vessel diameter. However, there is no ready
explanation for the differential rates in target-lesion revas-
cularization—more than one-third lower in stented patients
treated in BESMART and half again higher in BESMART
patients treated with balloon angioplasty alone. Part of the
explanation may reside in stent selection; stents composed
of narrower filaments may be particularly advantageous in
vessels with small lumina. Although the question of whether
or not to stent small vessels still remains unanswered, it is
nevertheless clear that the rheology of small vessels needs to
be thought about differently from that of large vessels.
LATE-BREAKING CLINICAL TRIALS I
The Beta-Blocker Length of Stay Study (BLOSS) Trial: A
Randomized, Placebo-Controlled Trial of Beta-Blocker
Treatment for Reduction of Hospitalization After Cardiac
Surgery
STUART J. CONNOLLY, MD, FACC
HAMILTON GENERAL HOSPITAL, HAMILTON, ONTARIO,
CANADA
Although the atrial fibrillation (AF) that occurs in about
one third of patients undergoing cardiac surgery is generally
well tolerated and easily controlled, it is also associated with
prolonged hospitalization. However, it is unknown whether
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prevention of the arrhythmia, often accomplished with beta
blockers, will lead to earlier discharge. One thousand
patients were randomized in a double-blind fashion to
receive either metoprolol or placebo beginning 12 h after
cardiac surgery and continuing for 14 days or until dis-
charge; patients were enrolled preoperatively and random-
ized postoperatively. Oral metoprolol was initially given at
50 mg bid, but later in the trial the dosage was increased to
50 mg tid for patients without depressed left ventricular
function. An episode of postoperative AF lasting at least
1 min developed in 31% of the 500 patients randomized to
metoprolol and in 39% of the 500 control patients, a
significant difference (p 5 0.0098). The mean intensive care
unit length of stay was 39 h for metoprolol recipients and
31 h for patients given placebo, a nonsignificant difference.
The mean total hospitalization time, the study’s primary end
point, was also nonsignificantly higher in the actively treated
group: 155 h versus 152 h for controls. Post-hoc analysis
indicated the length of hospital stay was increased 9%
among patients who received the beta blocker at the lower
dosage compared with the control group; it was decreased
by 2% among those who received metoprolol at the higher
dosage. Significant predictors of postoperative AF included
advanced age, a history of preoperative AF, and valve
surgery as opposed to coronary artery bypass surgery. There
were no deaths and no differences in rates of other postop-
erative complications. The authors concluded that beta-
blocker prophylaxis reduces the likelihood of AF after
cardiac surgery but that this benefit does not translate into
reduced hospital length of stay.
Commentary. This study emphasizes the consequences
of a preventive strategy in terms of clinical outcomes. We
often assume that prevention of a complication will save
resources. In this case, it did not. Fortunately, in this
situation, there are many other reasons to give beta blockers
before cardiac surgery, but saving money by preventing AF
is not one of them.
The Estrogen Replacement and Atherosclerosis (ERA) Trial
DAVID M. HERRINGTON, MD, FACC
WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE,
WINSTON-SALEM, NORTH CAROLINA
Whether estrogen replacement therapy (ERT) can reduce
the risk of coronary artery disease (CAD) in postmeno-
pausal women remains highly controversial. A long history
of epidemiologic and observational studies suggesting a
positive effect was not supported by the only large, random-
ized trial to study the effect of ERT on clinical cardiovas-
cular outcomes in this population. The effect of ERT on
angiographic end points was examined in a trial in which
309 postmenopausal women with at least one documented
coronary stenosis .30% in severity were randomized
double-blind to receive either opposed or unopposed ERT
or placebo and were followed for a mean of 3.2 years.
Treatment consisted of 0.625 mg/day conjugated equine
estrogen with (n 5 104) or without (n 5 100) 2.5 mg/day
medroxyprogesterone acetate, or placebo (n 5 105). The
average rate of treatment compliance was significantly lower
(74.5%) in the unopposed-ERT group than in the opposed-
ERT or control groups (84% and 85.8%, respectively) (p 5
0.03). At follow-up, levels of low-density-lipoprotein cho-
lesterol were significantly reduced, and levels of high-
density-lipoprotein cholesterol were significantly increased
in the two active-therapy arms compared with the placebo
arm. Angiographic follow-up was available in 248 patients,
or 80%, of those randomized. The primary outcome mea-
sure, change in mean minimum luminal diameter (MLD) of
the 10 standardized coronary segments from baseline to
follow-up quantitative angiography, showed no significant
differences among the three groups. Stratification of patients
according to baseline CAD severity also failed to disclose
any significant differences in MLD change among the three
treatment arms; nor were there any differences in rates of
clinical events, although the trial was not designed to
compare clinical outcomes.
Commentary. The more we learn about hormone re-
placement therapy (HRT), the more we realize how little we
know. This study provides negative evidence about the
impact of estrogen on vascular wall thickening and, in
concert with the results of the Heart and Estrogen-
Progestin Replacement Study (HERS) trial and the Wom-
en’s Health Initiative, casts a pall on the use of hormones to
prevent coronary heart disease events. The HERS trial
showed an excess of venous and arterial thrombotic events
in the first year after treatment with estrogen and progestin
in postmenopausal women without a uterus. After the first
year, the trends favored HRT, leaving a neutral trial result in
the end. The Women’s Health Initiative, which is testing
HRT in primary prevention, recently announced a similar
excess of thrombotic events, but the announcement stated
that the excess was not enough to stop the ongoing trial.
The clinical outcome results will be intriguing, as long-term
follow-up is accumulated in the Women’s Health Initiative.
These uncertain clinical trial results are surprising, consid-
ering that literally dozens of observational studies have
observed an association between HRT use and better
cardiovascular outcomes. Perhaps there is an important
lesson here about the necessity for large outcome trials for
common problems.
In-Hospital Results and Six-Month Clinical and
Angiographic Follow-Up of Coronary Stenting in Small
Coronary Arteries: Final Results of the BEstent in SMall
ARTeries (BESMART) Study
RENE A. KONING, MD
HOSPITAL CHARLES NICOLLE, ROUEN, FRANCE
Current recommendations do not support the use of coro-
nary stents for lesions in small arteries, those with reference-
segment diameters ,3 mm, because of the increased risk of
complications seen in observational studies. Several ran-
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domized trials demonstrated a superiority of stenting over
balloon angioplasty alone in larger vessel targets, but it
remains unknown whether the advantage also applies to
small vessels. In the multicenter BESMART trial, 381
patients with documented myocardial ischemia and a de
novo lesion #15 mm in length in a native coronary artery
with a reference-vessel diameter ,3 mm (mean: 2.2 mm)
were randomized to revascularization using either a stent or
balloon angioplasty alone. All patients received aspirin and
ticlopidine for one month, and aspirin thereafter. The two
treatment groups were similar with respect to baseline
demographic, angiographic, and clinical history, with the
exceptions that significantly more of the 192 stented pa-
tients were diabetic, 22% versus 12% of the 189 patients
treated with a balloon only (p 5 0.008), and more were
hypertensive, 51% versus 40% (p 5 0.034). In both treat-
ment groups, the mean maximal inflation pressures were
similar, and 2.5-mm balloons were used almost exclusively.
The rate of treatment crossover from balloon to stenting
because of poor balloon angiographic outcome was 24%.
Angiographic outcomes were significantly better in the
stented patients. The rates of restenosis (recurrence of at
least 50% severity) by quantitative angiography at six
months on an intention-to-treat basis, the primary end
point (available for 91% of patients), were 22.7% for stented
patients and 48.8% for patients treated with a balloon only
(p 5 0.0001). The rates of target-lesion revascularization at
six months were 13% and 25%, respectively (p 5 0.016). No
other differences in clinical end points were observed either
in-hospital or at six months.
Commentary. Despite advances in technical and phar-
macologic advances in percutaneous coronary intervention,
small coronary arteries continue to pose a challenge for the
interventionalist. Approximately one third of coronary in-
terventions are now performed in vessels ,3.0 mm in
diameter; as the population ages and the incidence of
diabetes increases, this proportion is likely to increase.
Because smaller vessels leave little margin for error, the rates
of both procedural complications and restenosis are higher
in small vessels. The issue of whether or not to place
intracoronary stents in small vessels continues to vex inter-
ventional operators. Two randomized studies presented at
the Annual Scientific Session, this one and the ISAR-
SMART trial, have arrived at opposite conclusions on the
same issue. Although the trials are similar in many aspects,
several important differences do exist and may have some
bearing on explaining the trials’ divergent findings. Among
these differences are the differential rates of angiographic
follow-up (81% for ISAR-SMART and 91% for BE-
SMART), the differing definition of “restenosis” (70% for
ISAR-SMART and 50% for BESMART), and the routine
use of the glycoprotein IIb/IIIa antagonist abciximab in
ISAR-SMART. It is interesting that the proportion of
stented patients with recurrent stenoses is very similar
between the two trials; however, it appears that a substantial
number of patients treated with conventional balloon an-
gioplasty had recurrent stenoses between 50% and 70% of
the vessel diameter. However, there is no ready explanation
for the differential rates in target-lesion revascularization—
more than one-third lower in stented patients treated in
BESMART and half again higher in BESMART patients
treated with balloon angioplasty alone. Part of the explana-
tion may reside in stent selection; stents composed of
narrower filaments may be particularly advantageous in
vessels with small lumina. Although the question of whether
or not to stent small vessels still remains unanswered, it
is nevertheless clear that the rheology of small vessels
needs to be thought about differently from that of large
vessels.
Intracoronary Gamma Radiation for Diffuse In-Stent Resten-
osis: A Two-Center Randomized Clinical Study—The
Washington Radiation for In-Stent Restenosis Trial for Long
Lesions (LONG WRIST)
RON WAKSMAN, MD, FACC
WASHINGTON HOSPITAL CENTER, WASHINGTON, D.C.
Three randomized trials have shown that vascular brachy-
therapy using gamma radiation for the percutaneous treat-
ment of in-stent restenosis can reduce the risk of recurrence,
but those trials did not include long, diffuse target lesions,
which remain a special challenge to percutaneous interven-
tions. The investigators of this study evenly randomized 120
symptomatic patients with diffuse in-stent restenotic lesions
36 mm to 80 mm (mean stent length: 70 mm) with coronary
reference-segment diameters of 3 mm to 5 mm, to receive
either a ribbon bearing 192Ir seeds or placebo seeds delivered
to the target site via a noncentered, closed-lumen catheter.
The radiation dosage consisted of 14 Gy to 15 Gy to a
2-mm distance from the center of the source. The mean
dwell time was 19 min. Debulking of the target lesion had
been carried out using rotational atherectomy in approxi-
mately two thirds of the patients in each group. Patients
were treated with either ticlopidine or clopidogrel for 30
days. Twenty-eight patients in the control group crossed
over to receive active therapy. Quantitative angiography at
six months disclosed rates of restenosis, defined as recurrent
lesions .50% of the reference-segment luminal diameter, of
32% in the irradiated group and 71% in the control group
within the stented segment only (p 5 0.0002). Rates of
restenosis considering only the segment containing the
lesion were 46% and 78%, respectively (p 5 0.03). The
six-month rates of major adverse cardiac events (death,
nonfatal Q-wave or non–Q-wave myocardial infarction,
target-lesion revascularization [TLR]) were 38.3% and
61.7%, respectively (p 5 0.01), with most of the significant
difference accounted for by the TLR component, the rates
for which were 30% and 60%, respectively (p 5 0.001). The
combined rate of total target-vessel occlusion or late throm-
bosis at any time during the follow-up was 15% of irradiated
patients and 6.7% of controls. The investigators concluded
that vascular brachytherapy using gamma radiation for
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diffuse in-stent restenosis lesions significantly reduces the
risk of recurrence at six months.
Commentary. Few findings are more disappointing to
the interventionalist than the discovery, upon restudy of a
patient who has received an intracoronary stent, that the
lumen has become narrowed in a diffuse pattern. Although
this disease is frequently referred to as in-stent “restenosis,”
in many cases the recurrent stenosis is worse than the
original narrowing. The LONG WRIST study was per-
formed by a group that had previously reported that a
second in-stent restenosis occurred after repeat intervention
in approximately 75% of patients who exhibited a diffuse
pattern of renarrowing. Debulking techniques initially ap-
peared to offer some promise of reducing this rate; however,
current findings also suggest that they are less than success-
ful. The LONG WRIST study appears to offer some hope
that gamma irradiation may help improve this dismal
situation, but this improvement must be noted with two
caveats. First, even with gamma irradiation, nearly half the
lesions treated had evidence of a second restenosis, and
more than one third required a third intervention. Second,
the rates of total occlusion and late thrombosis were
surprisingly high, especially in the irradiated group. Thus,
the findings of the LONG WRIST study should be viewed
as an improvement, rather than a cure, for a particularly
vexing disease process.
Pharmacokinetics (PKs) and Pharmacodynamics (PDs) of
Sotalol in a Pediatric Population: Results of the First
Controlled PK/PD Study of an Antiarrhythmic Agent in
Children
J. PHILIP SAUL, MD, FACC
MEDICAL UNIVERSITY OF SOUTH CAROLINA, CHARLESTON,
SOUTH CAROLINA
Heretofore, no PK or PD studies of d,l-sotalol, a class III
antiarrhythmic agent with beta adrenergic– blocking
properties, had been conducted in children. The investi-
gators enrolled a total of 59 patients age #12 years with
supraventricular or ventricular tachycardia to follow one
of two protocols. In the first, a pure PK study, a single
sotalol dose of 30 mg/m2 (selected as being one third of
an initial adult daily dose) was administered to 34
patients and followed by the taking of 10 blood samples
over 36 h. In the second protocol, a mixed PK/PD study,
ascending doses of 10 mg/m2, 30 mg/m2, and 70 mg/m2
were given to 25 patients every 8 h (based on some prior
anecdotal data and contrasting with the adult dosing
interval of every 12 h) for three days. Blood sotalol level
sampling and electrocardiography were performed at
baseline and during the 8-h interval following each of the
third, sixth, and ninth doses. Patients were stratified by
age group: 1) neonates, birth to 30 days; 2) infants and
toddlers, ages .30 days to 24 months; 3) young children,
ages 2 to 6 years; and 4) older children, ages 7 to 12 years.
Their weights ranged from 2 kg to 54 kg, their heights
ranged from 2 kg to 54 kg, their heights ranged from
46 cm to 146 cm, and their body surface areas (BSAs)
ranged from 0.17 m2 to 1.5 m2. Absolute creatinine
clearance ranged from 2 mL/min to 135 mL/min. Both
the clearance of sotalol and the volume of sotalol distri-
bution were linearly correlated with BSA (r2 5 0.89 and
0.86). Creatinine clearance adjusted for BSA was mark-
edly and consistently lower in the neonate group than in
the older age groups, consistent with the reduced matu-
ration of renal function in the first months of life.
However, clearances of sotalol and creatinine were lin-
early correlated to a highly significant degree in all age
groups (r2 5 0.87). The degree of QTc prolongation, a
measure of the agent’s class III properties, was signifi-
cantly increased among patients with a BSA ,0.33 m2,
compared with larger patients (p , 0.05). Changes in
relative risk interval, an indicator of the drug’s beta-
blocking effect, were also increased in the smallest pa-
tients, but significantly only at the lowest-dose level of 10
mg/m2. The mean terminal sotalol half-life over all
patients in the PK study, 9.5 h, was lower than the adult
range of 10 h to 17 h, prompting the use of every-8-h
dosing in the PK/PD study. It was concluded that sotalol
should be administered every 8 h at a dosage based on
BSA in children age #12 years who have normal renal
function. Extra caution should be observed when deter-
mining an initial dosage for neonates and other children
of very small body size, in whom maximum blood
concentrations of the drug and clinical effects are en-
hanced.
Commentary. The term “therapeutic orphan” was
coined to describe the pediatric population. More than 75%
of prescriptions for children are written for non–Food and
Drug Administration (FDA)-approved indications for
medications, and very few PK or PD studies have been done
in children. The market has been literally “too small” to
attract the attention of the industry, and the result has been
that pediatricians have had to use pharmaceuticals at their
own, and their patients’, risk. This study underscores an
urgent need for additional research of this kind. Many
pediatricians have been using the wrong dose of sotalol, not
because of professional lassitude but because the correct
dose had not been determined. The FDA Modernization
Act created a six-month patent extension several years ago
for companies that do reasonable studies in children; the
result has been an explosion of pediatric trials. This is one of
the first important results to come from this far-reaching
public policy initiative.
Roxithromycin for Prevention of Restenosis After Stenting
FRANZ-JOSEF NEUMANN, MD
DEUTSCHES HERZZENTRUM, MUNICH, GERMANY
Inflammatory processes associated with Chlamydia pneu-
moniae infection may modulate the prothrombotic proper-
ties of coronary plaques and promote neointimal prolifera-
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tion after percutaneous intervention. The authors
hypothesized that eradication of C. pneumoniae by antibiotic
therapy might influence angiographic and clinical measures
of restenosis after coronary stenting. Of 1,010 patients
undergoing coronary stenting, 506 were randomized also to
receive roxithromycin 300 mg once daily for 28 days, and
504 were randomized to a placebo. All patients received
aspirin and ticlopidine. About one half of the patients were
experiencing an acute coronary syndrome at randomization.
Coronary stenting was performed at inflation pressures of
14 atm to 15 atm; the mean acute residual stenosis severity
was ,6%. Angiographic restenosis was defined as 50%
diameter stenosis. The restenosis rate by quantitative an-
giography at six months, the primary end point, was 31.5%
in the actively treated group and 29.3% in the control group
(p 5 0.45). The rates of target-vessel revascularization
(TVR) at six months were 21% and 18.9%, respectively (p 5
0.41). The six-month late-loss index was nearly the same in
the two groups, 1.20 6 0.83 and 1.17 6 0.86, respectively.
The 30-day composite rate of death, nonfatal myocardial
infarction (MI), and TVR was 3.2% in the group treated
with roxithromycin and 2.8% in the placebo group (p 5
0.72). The combined rates of death or nonfatal MI were
2.6% and 2.4%, respectively (p 5 0.85).
Eight-month curves for survival free of Q-wave MI
suggested a disadvantage among actively treated patients,
but the difference was not significant. The findings do not
support a major role for C. pneumoniae in the pathogenesis
of thrombosis or restenosis after coronary stenting.
Commentary. Once associated primarily with sexual
activity and cigarette smoking, Chlamydia infection has
received new prominence in the world of cardiology as the
role of inflammation in ischemic heart disease becomes
recognized. After finding elevated anti-chlamydial titers in
the blood of patients with atherosclerosis and in coronary
atherectomy specimens, it seems natural that the role of
chlamydial infection in patients with ischemic complica-
tions of intracoronary stenting should be investigated. Un-
fortunately, the appropriate antibiotic dosing has not been
established. There are no reports on whether conventional
doses of tetracycline derivatives achieve tissue levels ade-
quate to eradicate infection in the walls of atherosclerotic
blood vessels, nor has the necessary duration of therapy been
established. This picture is further clouded by the fact that
no one has satisfied Koch’s postulates to establish a causative
role for chlamydial infection in unstable coronary syn-
dromes. Nonetheless, ROXIS is a well-designed attempt to
answer whether the current state of knowledge allows us to
select a dose of roxithromycin to eliminate putatively me-
diated effects of C. pneumonia on complications following
intracoronary stent placement. Considering the trend to-
ward benefit for clinical events at eight months in this trial,
the WIZAARD Trial, which is evaluating roxithromycin in
chronic coronary heart disease, will be an important com-
plementary effort.
LATE-BREAKING CLINICAL TRIALS II
SR90107A/ORG31540, a New Synthetic Pentasaccharide
(SP), as Adjunct to Fibrinolysis in ST-Elevation Acute
Myocardial Infarction (AMI): The Pentalyse Study
PATRICK K. COUSSEMENT, MD
UNIVERSITY HOSPITAL GASTHUISBERG, LEUVEN, BELGIUM
The disadvantages of unfractionated heparin (UFH) when
given as an adjunct to fibrinolytic therapy in AMI have led
to studies of potential alternatives. The investigators ran-
domized 333 patients with ST-elevation AMI, who were
treated within 6 h of chest-pain onset with a front-loaded
infusion of #100 mg t-PA, to receive one of two adjunctive
antithrombotic regimens: 1) UFH, given as an intravenous
bolus of 5,000 U, followed by an infusion of 1,000 U/h for
up to 72 h (n 5 86) or 2) SP in one of three dosages (4 mg
[n 5 84], 8 mg [n 5 80], or 12 mg [n 5 83]) given daily
for 5 6 1 days. The SP is a highly selective antithrombin
III–mediated inhibitor of activated factor X that does not
directly inhibit thrombin activity. Of the patients random-
ized, 326 received at least one dose of study medication and
became subjects of the analysis. Coronary angiography was
performed at 90 min in 321 patients and at an average of five
days in 250 patients. The 90-min rates of Thrombolysis In
Myocardial Infarction (TIMI) grade 3 flow in the infarct
artery were 68% in the UFH control group and 65%, 68%,
and 59% for patients in the 4 mg, 8 mg, and 12 mg SP
groups, respectively. The rates of TIMI grade 2 1 3 flow
were 82%, 79%, 85%, and 73%, respectively. None of these
differences was statistically significant. However, at late
angiography, a trend toward a higher and dose-related
increase in coronary artery patency was observed in patients
treated with SP. The TIMI 3 flow rates at a mean of five
days were 79% in the UFH control arm and 82%, 85%, and
90% for patients receiving 4 mg, 8 mg, or 12 mg SP,
respectively (p 5 NS). In patients with TIMI 3 flow at
90 min, the rate of TIMI 3 flow on the second angiogram
was 92% in all SP groups combined and 81% in the UFH
control group (p 5 0.6). Clinical event rates did not differ
significantly at 30 days. Patients who received SP showed a
trend toward reduced need for urgent revascularization; the
30-day incidence of this end point was 51% in the UFH
control arm and 37%, 39%, and 40% in the 4 mg, 8 mg, and
12 mg SP arms, respectively (p 5 NS). The combined
incidence of blood transfusion and intracranial hemorrhage,
the study’s primary safety end point, was 6.3% in all SP
groups combined and 7.1% in the UFH control arm (p 5
NS). The trial’s only instance of intracranial hemorrhage
occurred in the 4 mg SP arm. When transfusions related to
coronary artery bypass graft surgery were excluded, a trend
toward a lower transfusion rate was observed with SP,
compared with UFH control (3.3% vs. 7.1%; p 5 NS). The
results of this study supported the hypothesis that inhibition
of thrombin itself is not required during and after fibrino-
lytic therapy with t-PA as long as thrombin formation is
inhibited.
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Commentary. The PENTALYSE trial represents an-
other attempt to move “upstream” in the realm of antico-
agulation for syndromes of acute coronary injury. Heparin
consists of a mixture of complex polysaccharides. A basic
pentasaccharide sequence contained within the mixture is
responsible for catalyzing the cohesion of antithrombin
(AT) to factor Xa, while an 18-saccharide sequence leads to
the interaction of AT with factor IIa (thrombin). The SP
studied in PENTALYSE is a modified form of the naturally
occurring pentasaccharide that provides specific inhibition
of factor Xa. The SP did not provide statistically significant
improvements in early TIMI-3 flow. However, some en-
couraging statistically significant trends are present, partic-
ularly with regard to reduction of late re-occlusion.
The early period after thrombolysis is marked by intense
thrombin generation. Perhaps, as occlusive intracoronary
thrombus is degraded during thrombolysis, thrombin that
has previously been formed is released. If so, then some
antithrombin activity might be needed to inhibit thrombin-
induced platelet activation and cleavage of fibrin. Beginning
at 14 h within the PENTALYSE trial, thrombin-
antithrombin complexes were reduced in pentasaccharide-
treated patients compared with heparin-treated patients.
These findings may explain the late findings of the trial.
Measurement of pharmacodynamic parameters such as
anti-Xa activity and measures of fibrin generation and
activity would be helpful in interpreting the results of
PENTALYSE and determining whether the doses selected
for study provided adequate anticoagulant activity during
the early procoagulant storm that accompanies thrombolytic
therapy.
A Randomized Comparison of Low–Molecular-Weight
Heparin and Unfractionated Heparin (UFH) Adjunctive to
t-PA Thrombolysis and Aspirin (HART-II)
ALLAN M. ROSS, MD, FACC
GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER,
WASHINGTON, D.C.
Although the low–molecular-weight heparins have been
thoroughly tested in many of the treatment roles tradition-
ally occupied by UFH, they have not been systematically
studied as adjuncts to fibrinolytic agents in patients with
acute ST-elevation myocardial infarction (MI). As a prelude
to a randomized trial comparing enoxaparin and UFH as an
adjunct to recombinant t-PA, a pilot study was conducted in
which 20 patients with acute ST-elevation MI were ran-
domized to receive 100 mg t-PA over 90 min with aspirin
and either enoxaparin or UFH. Enoxaparin was given to
10 patients at a 30-mg intravenous (IV) bolus followed by
1 mg/kg SC twice daily for at least 72 h. Unfractionated
heparin was given to 10 patients as a weight-adjusted IV
bolus followed by a weight-adjusted IV infusion with a
target-adjusted partial thromboplastin time (aPTT) of
2–2.5 times control levels. Serial aPTT determinations
evidenced a relatively consistent effect over time for enox-
aparin, with the exception of spikes coincident with the IV
bolus and the initiation of t-PA. Serial aPTT readings
associated with UFH were highly variable and unpredict-
able. Based on the pilot study, a randomized angiographic
study was initiated in which 400 patients with acute
ST-segment elevation MI received the same fibrinolytic
therapy used in the pilot study. The patients were random-
ized to adjunctive enoxaparin (same regimen as used in the
pilot study, n 5 200) or UFH (4,000 U IV bolus for patients
#67 kg in weight or 5,000 U IV bolus for patients .67 kg,
followed by IV to a target aPTT of at least two times control
levels, n 5 200). The rates of TIMI grade 2–3 flow at
angiography performed 90 min after the start of the t-PA
infusion, the primary end point, were 80.1% for enoxaparin
and 75.1% for UFH. The relative increase among patients
who received enoxaparin was attributable mostly to an
increase in the rate of TIMI 3 flow (52.9% and 47.6%,
respectively). Of the patients with TIMI grade 2–3 flow at
90 min, 5.9% of those who received enoxaparin and 9.8% of
those who received UFH had angiographic evidence of
re-occlusion at one week. Clinical event rates were similar in
the two treatment groups: rates of in-hospital mortality
were 5.6% and 4.5%, respectively; 30-day mortality, 5% and
5%, respectively; predischarge emergency percutaneous re-
vascularization, 4% and 3%, respectively; major hemorrhage,
3.6% and 3.0%, respectively; and intracerebral hemorrhage,
1% and 1%, respectively. This study was constructed as an
equivalence trial, and all comparisons were well within the
equivalence ranged and trended strongly in favor of enox-
aparin over UFH. It was concluded that enoxaparin can be
substituted for UFH as an adjunct to fibrinolytic agents in
patients with acute ST-elevation MI.
Commentary. Unfractionated heparins have become in-
creasingly popular in the management of patients with acute
coronary syndromes because of their established clinical
efficacy and because their predictable anticoagulant effect
renders them considerably easier to use than UFH. No-
where is the theoretical need for a predictable anticoagulant
response greater than in patients receiving thrombolytic
therapy. In HART II, the substitution of enoxaparin for
UFH led to a minor increase in early TIMI 3 flow and a
halving of the rate of angiographic re-occlusion. This
occurred at the cost of a small increase in major bleeding,
without an observed increase in the rate of intracranial
hemorrhage.
It is fairly well known that low–molecular-weight hepa-
rins possess a greater ratio of anti-Xa to anti-IIa activity
than UFHs. In the case of enoxaparin, this ratio is approx-
imately 3.6:1, compared with 1:1 for UFH. It is interesting
that the results of HART II parallel the results of
PENTALYSE in that there are few differences in early
TIMI 3 flow but more important differences in late re-
occlusion. Perhaps thrombolytic therapy will ultimately
involve the use of an adjunctive glycoprotein IIb/IIIa
antagonist during the early course and an Xa antagonist (or
low–molecular-weight heparin) after the initial course. Al-
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though these results are promising, the safety aspect of
combined low–molecular-weight heparin and thrombolytic
therapy has not been explored in nearly as much depth as
that of UFH and thrombolytic therapy. Unfortunately, the
development of heparin replacement molecules is con-
strained by the absence of adequate proof that heparin itself
is superior to placebo. Although well over 100,000 patients
have been treated with UFH in fibrinolytic trials, few have
been randomized to heparin or placebo. Thus, although the
results of HART II are promising, it is too early to
recommend routine use of low–molecular-weight heparin as
adjunctive therapy with fibrinolytic drugs.
Optimal Dosing of a Platelet Glycoprotein (GP) IIb/IIIa
Antagonist, Lamifiban, Using Renal-Based Algorithms, in
Patients With Acute Coronary Syndromes (ACS): Results
From the PARAGON B Study
ROBERT A. HARRINGTON, MD, FACC
DUKE UNIVERSITY MEDICAL CENTER, DURHAM, NORTH
CAROLINA
Treatment with platelet glycoprotein (GP) IIb/IIIa receptor
blockers can reduce the risk of death or acute myocardial
infarction (MI) when given to patients with ACS not
associated with persistent ST-segment elevation. Studies
heretofore have used weight-adjusted dosages of these
agents. Evidence suggests that lamifiban, a nonpeptide GP
IIb/IIIa blocker with a renal mechanism of clearance from
the circulation, might be more suited to renal-based dosing
methods. The PARAGON B study enrolled 5,225 high-
risk patients with ischemic chest pain within the previous
12 h and either ST-segment or T-wave changes or cardiac
enzyme or troponin readings suggestive of acute ischemic
syndromes. Patients were randomized to receive either
placebo or lamifiban as a 500-mg intravenous bolus fol-
lowed by an infusion of 1.0, 1.5, or 2.0 mg/min based on
calculated creatinine clearance over 72 h, to a maximum of
120 h following any percutaneous intervention. All patients
received aspirin and either unfractionated or low–
molecular-weight heparin. Sixty percent of patients under-
went cardiac catheterization, 27% underwent percutaneous
interventions, and 15% underwent coronary artery bypass
surgery, with no significant differences among randomiza-
tion groups. The composite rates of all-cause death, acute
MI, or severe recurrent ischemia, the trial’s primary end
point, were 12.8% in the 2,597 patients randomized to
placebo and 11.8% for the 2,628 patients randomized to
lamifiban (p 5 0.329). Death and MI constituted most of
the events making up the primary end point; the 30-day
rates of death or MI were 11.5% in the placebo group and
10.6% in the lamifiban group (p 5 0.320). There was no
significant difference between randomization groups with
respect to rate of hemorrhagic stroke. There was an excess of
moderate bleeding (blood transfusion or $5 g/dl drop in
Hgb) with lamifiban compared with placebo (14.0% vs.
11.5%, p 5 0.002). In a substudy encompassing 1,160 of the
randomized patients who underwent serial assessments of
cardiac troponin T, among those who were troponin-
positive, the primary 30-day rates of death or MI were 19%
or 11%, respectively (p 5 0.018).
Commentary. Much attention has recently been paid to
the variability of individual patients’ responses to GP
IIb/IIIa antagonists. Although experimental data suggest
that blockade of approximately 80% of platelet surface GP
IIb/IIIa receptors represents the threshold necessary to
interfere with platelet participation in thrombosis, clinical
data to confirm this concept are scant. Notably, when two
different doses of lamifiban were studied in the first
PARAGON trial, both ischemic coronary events and bleed-
ing were more common among patients assigned to receive
the higher dose. The PARAGON B study was subsequently
designed to test an observation from the first PARAGON
trial. In that trial, separation of patients according to blood
levels of lamifiban revealed that event rates were approxi-
mately 50% lower in patients whose blood levels were
between 20 and 40 ng/mL. Because of lamifiban’s binding-
affinity for GP IIb/IIIa, these levels represent an interme-
diate level of receptor blockade.
Although lamifiban did not reduce ischemic event rates
significantly in the PARAGON B study, the findings are very
consistent with other trials of GP IIb/IIIa antagonists in ACS.
There was an approximate 1% absolute reduction in the
composite rate of death or MI, and the reductions were
greatest in patients undergoing early percutaneous coronary
intervention and those with elevated troponin levels. In both of
these settings, there is objective evidence of acute arterial injury
at the time when GP IIb/IIIa receptors are blocked. In a
broader perspective, it seems unlikely that lamifiban will be
developed as a therapeutic agent. However, these findings do
lend further support to the use of GP IIb/IIIa antagonists in
patients with ACS, particularly in patients who have objective
evidence of ischemia.
A Randomized Comparison of Sibrafiban, an Oral
Glycoprotein (GP) IIb/IIIa Receptor Antagonist, With and
Without Aspirin Versus Aspirin After Acute Coronary
Syndromes (ACS): Results of the Second SYMPHONY Trial
L. KRISTIN NEWBY, MD, FACC
DUKE UNIVERSITY MEDICAL CENTER, DURHAM, NORTH
CAROLINA
Intravenous GP IIb/IIIa receptor blockers reduce the risk of
ischemic events in patients with ACS, but a similar benefit
for chronic oral GP IIb/IIIa blockers compared with aspirin
alone has yet to be demonstrated. A first SYMPHONY trial
found that one such oral agent, sibrafiban, given without
aspirin did not reduce ischemic risk in patients with ACS
compared with aspirin alone. A second SYMPHONY trial
was initiated to attempt the same comparison, using sibra-
fiban plus aspirin. A total of 8,400 patients with stabilized
ACS were expected to be randomized to receive either
low-dose sibrafiban with aspirin, high-dose sibrafiban alone,
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or aspirin alone for at least one year. Sibrafiban dosing was
based on weight and serum creatinine, with the goal of
either .25% (low-dose group) or .50% (high-dose group)
steady-state inhibition of platelet aggregation. Following a
negative finding in the first SYMPHONY trial, the second
SYMPHONY trial was terminated by the sponsor after
only 6,671 patients had been enrolled. As a result of
randomization, 2,232 patients received aspirin plus low-
dose sibrafiban, 2,174 patients received aspirin plus high-
dose active therapy, and 2,231 received aspirin only; patients
were treated for a mean of 90 days. The composite rates of
death, acute myocardial infarction (MI), or severe recurrent
ischemia, the primary efficacy end point, were not signifi-
cantly different: 9.2%, 10.5%, and 9.3%, respectively. How-
ever, patients who received high-dose sibrafiban showed
significant increases in some secondary end points compared
with those randomized to aspirin only. The rates of death or
MI were 6.8% in the low-dose group, 8.6% in the high-dose
group, and 6.1% in the aspirin-only group (p 5 0.004 for
the high-dose sibrafiban group compared with the aspirin
group). Mortality alone was 1.7%, 2.4%, and 1.3%, respec-
tively (p 5 0.008 for the high-dose sibrafiban group
compared with the aspirin group). The MI rate alone was
5.3%, 6.9%, and 5.3%, respectively (p 5 0.03 for the
high-dose sibrafiban group compared with the aspirin
group). The composite rates of major or minor bleeding, a
primary safety end point, were 21.1% and 22.1% for the
low- and high-dose sibrafiban groups, respectively—
significantly higher than the 11.7% rate for aspirin-only
patients. Patients who received low-dose active therapy had
a 43% increase in risk of major bleeding complications
compared with the aspirin group.
Commentary. The second SYMPHONY trial repre-
sents an attempt to extend the benefits of GP IIb/IIIa
antagonism to secondary prevention after initial presenta-
tion with an ACS. Unfortunately, the contrast between the
intravenous and the oral GP IIb/IIIa antagonists is dra-
matic. Although trials of the intravenous agents have almost
universally indicated a 10% to 15% reduction in the com-
posite of death or MI, the second SYMPHONY is the
fourth consecutive negative trial of an oral agent. Even
worse, all four trials of oral GP IIb/IIIa antagonists have
shown an increase rather than a decrease in mortality.
Although it has been hoped that improved pharmacokinet-
ics—specifically more avid binding of GP IIb/IIIa and more
predictable bioavailability—would provide an advantage for
newer oral GP IIb/IIa antagonists, the promise has been thus
far unfulfilled. Two potential reasons need to be considered:
first, the efficacy of GP IIb/IIIa antagonism appears to be
related to the temporal proximity of receptor blockade to the
initial arterial injury. It is greatest in trials of percutaneous
coronary intervention, when the antagonist is administered
immediately before balloon inflation, somewhat less in trials of
ACS when 12 h to 24 h have elapsed after the injury has
occurred, and least in the secondary prevention trials if the oral
agent is given at least 72 h after presentation. The decreased
efficacy must be balanced against a more prolonged period of
drug exposure and, hence, bleeding risk over the longer time
period when oral GP IIb/IIIa antagonists are administered. A
second reason that has been postulated for the failure thus far
of the oral agents concerns other biological effects of the drugs.
In addition to permitting platelet aggregation, GP IIb/IIIa
may also mediate platelet activation through a process known
as “outside-in-signaling.” Occupancy of the receptor may
prevent aggregation from occurring but may at the same time
activate the platelet, rendering it more, rather than less, likely
to participate in thrombosis during trough periods between
oral doses. Most recently, concerns have been raised that the
oral agents induce a pro inflammatory state. The book is not
yet closed, however, concerning oral GP IIb/IIIa antagonism.
A second generation of agents has been developed. These
newer agents bind GP IIb/IIIa with much higher affinity than
the first generation and thus have the potential to avoid some
of the problems associated with receptor occupancy–mediated
platelet activation. For the time being, however, oral antago-
nists of GP IIb/IIIa are not likely to come into clinical use in
the immediate future.
Randomized Comparison of Percutaneous Transluminal
Coronary Angioplasty (PTCA) of the Infarct Vessel and
Medical Therapy in Stable Survivors of Acute Myocardial
Infarction (AMI): The Post-Infarct PTCA Study of the
Arbeitsgemeinschaft Leitender Kardiologischer
Krankenhausarzte (ALKK)
UWE ZEYMER, MD
KLINIKUM KASSEL, KASSEL, GERMANY
Percutaneous revascularization of a significant infarct-
related artery (IRA) stenosis is often performed in stable
and symptom-free patients with a recent AMI. However,
there are no randomized studies to support this practice.
This study randomized 300 stable patients who had expe-
rienced an AMI within the previous one to six weeks (mean:
three weeks) and who had a significant IRA stenosis and no
critical lesions in other coronary arteries to undergo PTCA
or medical therapy. The 149 patients treated with PTCA
and the 151 who were medically managed were similar at
randomization with respect to stenosis severity and vessel
location and whether the IRA was occluded. The rates of
event-free survival at one year, the primary end point, were
90% and 82%, respectively (p 5 0.066). In a follow-up
extended to a mean of 53 months, available for 96% of
patients, the rates of death were 5% in the intervention
group and 10% in the medically managed group (p 5 0.1).
The rates of event-free survival were 76% and 67%, respec-
tively (p 5 0.1). Nitrate use, although similar in both groups
at baseline, at one year was significantly reduced among
patients who underwent intervention (38% vs. 67%, p 5
0.001). Use of beta blockers and calcium-channel blockers
remained comparable. The study suggests that PTCA does
not significantly reduce the rate of death and reinfarction in
stable survivors of AMI.
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Commentary. ALKK appears to be a new trial reaffirm-
ing an old message: despite the intuitive appeal of anatom-
ically directed revascularization, data collected in the current
era do not seem to differ appreciably from those collected a
decade and a half ago. ALKK differs from the oft-quoted
Thrombolysis In Myocardial Infarction (TAMI I), Throm-
bolysis and Angioplasty In Myocardial Infarction (TIMI
II), and European Cooperative Study Group trials in that
patients were not required to have undergone fibrinolytic
therapy and that intervention was performed somewhat later
than in the previous trials. We do not know the baseline
characteristics of these patients, but judging from the event
rates reported, the patients appear to be at relatively low
clinical risk. Similarly, technical details of the interventional
procedures are not reported, but it seems fair to assume that
intracoronary stents were used liberally and that GP IIb/IIIa
antagonists (in Europe, abciximab) were available. Al-
though this trial is small, its findings are concordant with
data produced in a number of previous trials and still
support an approach to intervention in stable, low-risk
survivors of AMI involving risk-stratification rather than
routine angiography.
High-Dose Eptifibatide in Elective Coronary Stenting:
Results of the ESPRIT Trial
JAMES E. TCHENG, MD, FACC
DUKE UNIVERSITY MEDICAL CENTER, DURHAM, NORTH
CAROLINA
ESPIRIT was an efficacy and safety study of a new dosing
regimen for the small-molecule GP IIb/IIIa inhibitor eptifi-
batide used as an adjunct to planned, elective coronary stenting.
Approximately 2,400 patients undergoing coronary stent
placement in native coronary arteries were expected to be
randomized to either adjunctive eptifibatide (180 mg/kg double
bolus, with boluses separated by 10 min, followed by 2.0
mg/kg/min infusion for 18 h to 24 h) or placebo in a
double-blind fashion. Heparin was administered to a target
activated clotting time of 200 s to 300 s. Almost all patients
also received ticlopidine or clopidogrel. Enrollment was termi-
nated in February 2000, when it was observed that active
therapy was associated with a significant 43% reduction in
relative risk of death or acute myocardial infarction (MI) at
48 h (4.9% in the active-therapy group vs. 8.6% in the control
group, p 5 0.0017). Outcomes at 48 h factor for the 1,040
patients randomized to eptifibatide and the 1,024 patients
randomized to placebo are available; analysis of outcomes at 30
days, six months, and one year are planned. The 48-h rates of
the primary end point—a composite of death, MI, urgent
target-vessel revascularization, or (placebo arm only) bailout
GP IIb/IIIa blockade—were 6.6% and 10.5%, respectively
(p 5 0.0015). Reductions in relative risk of all components of
the composite end point were also significant. The rates of
major and minor bleeding complications were statistically
similar in the two treatment groups; most such complications
consisted of femoral access-site bleeding. Intracranial hemor-
rhage occurred in two patients who received eptifibatide and
one in the placebo group.
Commentary. As GP IIb/IIIa blockade during inter-
vention has become more refined, the major reason most
interventional operators cite for withholding its use
during routine cases has been economic. The preliminary
results of ESPRIT indicate that this last argument is
likely to wither. The design of ESPRIT was based on
pharmacokinetic and pharmacodynamic observations
made in patients receiving eptifibatide during previous
trials. After a 180 mg/kg bolus is given and a 2 mg/kg/min
infusion is begun, levels of eptifibatide increase after the
bolus and then decrease for a period of approximately 4 h
before rising to a steady-state level. In ESPRIT, a second
bolus of eptifibatide was given 10 min after the first dose
to prevent this transient decrease in inhibition of platelet
aggregation. A previous trial of eptifibatide given at a
lower dose during percutaneous coronary intervention
(PCI) had shown a nominal but transient reduction in
ischemic events. In that trial, intracoronary stenting was
performed in fewer than 4% of patients, but in ESPRIT
it was performed in more than 95%. It is not known
whether this difference between the two trials is the result
of different dosing schedules or the fact that the proce-
dure of stenting changes the substrate of ischemic events
into one that is likely to be ameliorated by GP IIb/IIIa
blockade. It is also not known whether the short-term
results reported here will be robust enough to be present
at the end of one year, although, if the pattern seen in the
Evaluation of Platelet Inhibition with Stent study is
followed, this is likely to be the case. Clinicians who plan
to use eptifibatide based on the ESPRIT results should
keep two important points in mind: the procedures
studied were largely elective ones, and the dosing of
eptifibatide used here differs from that currently labeled
for either PCI or acute coronary syndromes (ACS). It is
also important to note that the model used to calculate
the eptifibatide doses is based on steady-state drug levels
obtained with a 2 mg/kg/min infusion. Therefore, pa-
tients who have received eptifibatide for more than 3 h to
4 h for the treatment of ACS do not need to receive a
further loading dose.
LATE-BREAKING CLINICAL TRIALS III
Outcomes of a Prospective Trial of Intravenous (IV)
Milrinone for Exacerbations of Chronic Heart Failure
(OPTIME-CHF)
MIHAI GHEORGHIADE, MD, FACC
(PRESENTER)
NORTHWESTERN UNIVERSITY SCHOOL OF MEDICINE,
CHICAGO, ILLINOIS
There have been few randomized, placebo-controlled trials
to guide the management of hospitalized patients with
worsening symptoms of chronic heart failure (CHF). Intra-
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venous positive inotropic agents can improve hemodynam-
ics and may aid the titration of standard oral drug therapy.
This study randomized 949 patients with worsening CHF
within 48 h of hospital admission to receive a 48-h infusion
of either milrinone (0.5 mg/kg/min IV without a loading
dose) or placebo and followed them for 60 days. Eligible
patients had worsening CHF with a left ventricular ejection
fraction #40% and did not require IV vasopressor or
inotropic support. Patients with unstable angina or acute
myocardial infarction within the prior three months were
excluded. The CHF was ischemic in etiology in 51% of both
treatment groups. The number of days of hospitalization for
cardiovascular causes within 60 days after randomization,
the primary end point, was a mean of 12.3 for the 477
patients who received milrinone and 12.5 for the 472
randomized to placebo (median, 6.0 and 7.0, respectively), a
nonsignificant difference. Similarly, there was no significant
difference in the mean number of days from initial discharge
to rehospitalization (5.7 days and 5.9 days, respectively), a
secondary end point. No significant differences were ob-
served with respect to subjective measures of CHF severity.
Milrinone treatment was associated with an increase in
relative risk of atrial fibrillation (AF) and a 10.7% increase
in relative risk for sustained hypotension, whereas placebo
was associated with a 1.5% increase in relative risk for AF
and a 3.2% increase in relative risk for sustained hypoten-
sion. The proportion of patients who failed to show clinical
improvement was similar in both treatment groups; how-
ever, 20.4% of actively treated patients and 9.0% of controls
required infusion adjustments because of an adverse effect,
primarily hypotension. Mortality was 3.8% and 2.3%, re-
spectively, in-hospital and 8.9% and 10.3%, respectively,
over 60 days; neither difference was significant. Multivariate
analysis indicated the following significant predictors of
death within 60 days: low systolic blood pressure (BP), low
serum sodium, advanced age, and New York Heart Asso-
ciation (NYHA) functional class. The following were sig-
nificant independent correlates of increased hospitalization
time over 60 days: low systolic BP, low serum sodium, male
gender, an increase in NYHA functional class, and the
number of hospitalizations over the previous year. When the
primary end point was analyzed based on CHF etiology,
patients with ischemic disease tended to have fewer hospi-
talization days when receiving placebo therapy, while the
opposite was true for the nonischemic group. Specifically,
milrinone was associated with fewer days of cardiovascular
hospitalization during follow-up (10.9 vs. 12.6 days). It
appears that patients with low serum sodium levels at
baseline and those with nonischemic heart failure tended to
do better with milrinone therapy, while the opposite was
true for patients without hyponatremia and with ischemic
heart failure. The OPTIME-CHF data suggest that, in
patients who do not require IV inotropic therapy, routine
use of IV milrinone is not recommended. This study does
not evaluate whether IV milrinone is beneficial in the other
subsets of patients with more severe heart failure.
Commentary. This trial is the first reasonably large
randomized trial in patients with acutely decompensated
heart failure. The use of inotropic agents in heart failure has
been controversial because of increased mortality in trials in
which patients were treated over the long term with orally
active agents. Surprisingly few outcome data have been
available, despite the widespread use of intravenously ad-
ministered inotropic agents. Although the trial failed to
demonstrate a benefit in the expanded indication of early
milrinone use in decompensated heart failure, it did provide
evidence of safety in patients with severe heart failure as
manifested by a low serum sodium and those with a
nonischemic etiology. Much more evidence is needed in this
field, considering that heart failure is the most common
reason for hospitalization in Medicare, that it carries a
substantial mortality risk, and that almost nothing is known
about which therapies are effective.
Prospective Randomized Amlodipine Survival Evaluation
(PRAISE-2)
MILTON PACKER, MD, FACC
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SUR-
GEONS, NEW YORK, NEW YORK
The first PRAISE trial randomized 1,153 patients with
ischemic or nonischemic New York Heart Association
(NYHA) class IIIB–IV heart failure to receive amlodipine
(up to 10 mg/day) for up to 33 months. No significant
benefit of amlodipine therapy was observed with respect to
the combined primary end point of death or cardiovascular
hospitalization, although the agent demonstrated a nonsig-
nificant trend toward improved mortality. Solely among
patients with nonischemic heart failure, however, amlodip-
ine was associated with a 45% reduction in risk of death
(p 5 0.001), leading the investigators to conduct a PRAISE
2 trial to explore the finding further. The study randomized
1,652 patients with nonischemic NYHA class IIIB–IV
heart failure to receive amlodipine (up to 10 mg daily, n 5
826) or placebo (n 5 826) and followed them for 48 months
for a primary end point of all-cause mortality. The protocol
mirrored that of the previous trial in virtually every respect.
By intention-to-treat, all-cause mortality was 33.7% in the
amlodipine group and 31.7% in the placebo group (p 5
0.32). In the combined analysis of outcomes data from
patients in the first and second PRAISE trials, all-cause
mortality was 33.4% among those who received amlodipine
and 34.0% among those who received placebo (p 5 0.81).
The results of PRAISE 2 do not support the apparently
favorable effect of amlodipine on survival for patients with
nonischemic heart failure observed in the first PRAISE
trial. Combined analysis of both trials suggests that amlo-
dipine has neither a favorable nor an unfavorable effect on
mortality in patients with severe chronic heart failure.
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Commentary. This surprising result should sound a note
of caution for anyone who accepts marginal evidence of a
mortality benefit. The Evaluation of Losartan in the Elderly
(ELITE) I trial similarly showed a substantial apparent
benefit of losartan compared with captopril, but the larger
ELITE II showed a trend in favor of captopril. Similarly, a
small trial with vesnirinone was markedly positive compared
with placebo, but a larger follow-up trial had to be stopped
because of excessive mortality with vesnirinone. The mes-
sage here is clear: we need a substantial number of deaths
(perhaps 200–300) in heart failure trials before a stable
estimate of the effectiveness of the treatment can be reached.
Seven-Year Outcome in the Bypass Angioplasty
Revascularization Investigation (BARI) by Treatment and
Diabetic Status
KATHERINE M. DETRE, MD, FACC
UNIVERSITY OF PITTSBURGH, PITTSBURGH, PENNSYLVANIA
Analysis of five-year survival in the BARI trial, which has
been published previously, disclosed no significant differ-
ence in survival between patients randomized to coronary
artery bypass grafting (CABG) or percutaneous translumi-
nal coronary angioplasty (PTCA). However, in the retro-
spectively defined subgroup of patients with diabetes mel-
litus, patients treated with CABG showed a significant
survival advantage. The trial randomized 1,829 patients
with symptomatic multivessel disease and no prior coronary
revascularization to undergo either CABG or PTCA as an
initial treatment strategy. Patients were required to be
angiographically eligible for either procedure. Patients have
been followed for an average of 7.8 years. In the analysis of
outcomes at seven years, the rate of survival for the popu-
lation as a whole was 84.4% for those who underwent
CABG and 80.9% for those who received PTCA (p 5
0.043). The subgroup of 353 patients with treated diabetes
mellitus accounted for virtually all of the difference in
survival. Among diabetics, the seven-year survival rates were
76.4% and 55.7%, respectively (p 5 0.0011). Their rates of
survival free of acute myocardial infarction (MI), a second-
ary end point, were 65.2% and 50.0%, respectively (p 5
0.049). Among the remaining 1,476 patients without dia-
betes, the seven-year survival rates were almost identical at
86.4% and 86.8%, respectively (p 5 0.72). The rates of
MI-free survival among nondiabetics were 77.8% and
78.9%, respectively (p 5 0.57). Patients randomized to
CABG had a significantly lower rate of subsequent coronary
revascularization than did patients who underwent PTCA:
13.1% and 59.7%, respectively (p 5 0.001). It was con-
cluded that CABG is associated with significantly improved
seven-year survival compared with PTCA in the overall
BARI population of patients with symptomatic multivessel
disease. Improvement in the seven-year survival rate was
highly significant with CABG among diabetic patients.
Survival at seven years among nondiabetic patients was
virtually the same with either CABG or PTCA.
Commentary. The news from BARI is most likely
disappointing to interventional cardiologists. However, it is
very consistent with earlier results of the trial, which
demonstrated a nonsignificant survival trend favoring
CABG five years after randomization. As in the previously
reported results, the difference was nearly completely ac-
counted for by patients with diabetes mellitus. Although it
can, and should, be argued that current interventional
technique, namely stenting and GP IIb/IIIa antagonism
with abciximab, were not included in BARI (for obvious
reasons), the advantages of these treatments must also be
placed in the correct context. Abciximab has been shown to
reduce the periprocedural risk of diabetics to a level similar
to that of nondiabetics and perhaps reduces the rate of
in-stent restenosis in patients with diabetes. Although
intracoronary stenting reduces the rate of recurrent stenoses
in patients with diabetes, it is not clear whether these rates
are reduced to levels seen in nondiabetic patients. It should
also be noted that the increased risk in patients with
diabetes did not occur during hospitalization, but it accu-
mulated gradually over the follow-up period. That the
BARI investigators found the risk reduction to be confined
to patients for whom the internal mammary artery was used
as a surgical conduit suggests that the extent of coronary
artery disease, rather than procedural factors, was responsi-
ble for the findings. Unfortunately, the investigators in-
volved in the multiple trials of percutaneous coronary
intervention versus CABG done around the world have
been unable to pool their data. A systematic overview would
provide the important evidence for replication that is gen-
erally required before adopting a major therapeutic strategy
change. The seven-year findings should, therefore, at the
very least, lead to a clear note of caution when planning
percutaneous procedures in diabetic patients with multives-
sel disease.
Outcomes 15 Years After Valve Replacement With a
Mechanical Versus a Bioprosthetic Valve: Final Report of the
Veterans Administration (VA) Randomized Trial
SHAHBUDIN H. RAHIMTOOLA, MD, MACC,
ON BEHALF OF THE VA INVESTIGATORS
UNIVERSITY OF SOUTHERN CALIFORNIA, LOS ANGELES,
CALIFORNIA
The VA Randomized Trial was launched in 1976 to
compare the long-term outcomes of bioprosthetic and
mechanical prostheses for aortic valve replacement (AVR)
and mitral valve replacement (MVR). Five-year and 10-year
follow-up results have been published previously. The co-
hort has now been followed up for 15 years. Among the 394
patients who underwent AVR, all-cause mortality at 15
years was 66% for those randomized to mechanical valves
and 79% for those randomized to bioprostheses (p 5 0.02).
Survival curves for patients with AVR began to diverge after
year 10 in such a way that the 13% absolute difference
comprised an approximately 2.5% per year absolute differ-
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ence in mortality from years 10 to 15. The 15-year mortality
rates for valve replacement in the mitral position were 81%
for patients randomized to mechanical valves and 79% for
patients randomized to a bioprosthesis (p 5 0.30). The rate
of primary valve failure was significantly increased with the
bioprosthesis at both valve locations; the rates were 0% for
mechanical valves and 23% for bioprosthetic valves for AVR
(p 5 0.0001) and 5% and 44%, respectively, for MVR (p 5
0.0002). Among patients ,65 years of age, the rate of
primary valve failure was also significantly increased with
the bioprosthesis at both valve locations: 0% for mechanical
valves and 26% for bioprosthetic valves for AVR (p 5
0.001) and 4% and 44%, respectively, for MVR (p 5
0.0001). Among patients $65 years of age, the primary
valve failure rate in the aortic position was 0% for mechan-
ical valves and 9% for bioprosthetic valves (p 5 0.16).
Among patients undergoing AVR, the need for repeat valve
replacement was 10% for mechanical valves and 29% for
bioprosthetic valves (p 5 0.0004). Bleeding complications
were significantly more common in patients randomized to
mechanical valves: the bleeding complication rate was 51%
for mechanical valves and 30% for the bioprostheses for
AVR (p 5 0.0001) and 53% and 31%, respectively, for
MVR (p 5 0.01). The rates of valve-related complications
and of thromboembolism were not significantly different for
valve replacement at either location. It was concluded that,
15 years after randomization, patients who underwent AVR
had a significantly better survival with a mechanical valve
than with a bioprosthesis, largely because of the former’s
primary failure rate of essentially zero. Primary valve failure
was significantly more common for bioprostheses than for
mechanical valves among patients ,65 years. Primary valve
failure rates were not significantly different after AVR
among patients $65 years.
Commentary. The long-term follow-up from this VA
study is not surprising, but it raises a number of interesting
issues. The current paradigm for cardiac valve development
is focused on intensive engineering standards and registries
rather than randomized trials. This study demonstrates the
need for methodologic development on two fronts: how to
distinguish modest differences between valves in clinical
outcomes without requiring randomized trials that are not
affordable by the device industry and how to reliably
measure long-term outcomes when we cannot wait for
long-term outcomes before putting a new valve on the
market.
Assessment of Cardioversion Using Transesophageal
Echocardiography (TEE) Multicenter Study (ACUTE I):
Clinical Outcomes at Eight Weeks
ALLAN L. KLEIN, MD, FACC
CLEVELAND CLINIC FOUNDATION, CLEVELAND, OHIO
The use of TEE to screen for the presence of left atrial
thrombi in patients with atrial fibrillation (AF) has the
potential for reducing the duration of anticoagulation before
cardioversion. A total of 1,222 patients with either AF of
.2-days duration or atrial flutter and a history of AF, and
who were candidates for direct-current cardioversion
(DCC), were randomized to undergo DCC using either a
TEE-guided or conventional approach. Patients who re-
quired long-term anticoagulation, who were hemodynami-
cally unstable, or who had contraindications to anticoagu-
lation or TEE were excluded. Patients assigned to the TEE
group were to undergo TEE preceded by brief anticoagu-
lation. In the absence of thrombus, DCC was to be
performed, followed by four weeks of warfarin therapy.
With thrombus present, patients were instead to receive
warfarin for three weeks, followed by repeat TEE; then, in
the absence of thrombus, the patients were to have DCC,
followed by four weeks of warfarin, or, in the presence of
thrombus, they were instead to receive another four weeks
of warfarin. Patients assigned to the conventional DCC
strategy were to receive warfarin for three weeks, followed
by DCC, then followed by another four weeks of warfarin.
Of the 619 patients randomized to the TEE-guided ap-
proach, TEE was performed in 551; of the 551, 427 had
DCC, which was successful in 344 patients. Of the 603
patients randomized to the conventional strategy, 367 un-
derwent DCC, which was successful in 293 patients; spon-
taneous conversion was the most common reason that DCC
was not performed in the remaining 236 patients. On an
intention-to-treat basis, the rate of the primary composite
end point of stroke, transient ischemic attack, or peripheral
embolism was 0.81% in the TEE-guided DCC group and
0.50% in the conventional-strategy DCC group (p 5
0.501). With respect to secondary end points, the rates of
major bleeding were 0.81% and 1.50%, respectively (p 5
0.261), the rates of minor bleeding were 2.30% and 4.0%,
respectively (p 5 0.084), and the composite rates of major
or minor bleeding were 3.11% and 5.50%, respectively (p 5
0.025). No significant differences were observed in rates of
other secondary end points, including all-cause mortality,
cardiac mortality, achievement of sinus rhythm at eight
weeks, and functional capacity at eight weeks. It was
concluded that the TEE-guided approach with short-term
anticoagulation does not reduce the risk of embolic events
over eight weeks but may decrease the risk of major or
minor bleeding complications. Furthermore, the TEE-
guided approach allows for earlier cardioversion of AF but
does not improve the rate of sinus conversion, functional
capacity, or survival at eight weeks. TEE-guided DCC of
AF may be considered an alternative to the conventional
approach.
Commentary. This investigator-initiated trial will gen-
erate a substantial amount of important information about
cardioversion, but the low event rate with the traditional
approach is already one surprising result of the study.
Indeed, with event rates this low, it is difficult to envision a
scenario in which TEE could lead to a clinical benefit,
although the economic benefit of avoiding four additional
weeks of anticoagulation could be substantial.
324 Kleiman and Califf JACC Vol. 36, No. 1, 2000
Late-Breaking Clinical Trials July 2000:310–25
Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack (ALLHAT) Trial: Interim Results
BARRY DAVIS, MD
UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH,
HOUSTON, TEXAS
CURT D. FURBERG, MD, PHD
WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE,
WINSTON-SALEM, NORTH CAROLINA
The ALLHAT trial has randomized 42,448 hypertensive
patients with multiple cardiovascular risk factors to undergo
long-term double-blind therapy with either a diuretic
(chlorthalidone) or one of three alternatives: a calcium-
channel blocker (amlodipine), an angiotensin-converting
enzyme inhibitor (lisinopril), or an alpha-adrenergic blocker
(doxazosin). The trial also includes a randomized, open-
label evaluation of statin therapy in the hypercholester-
olemic subset of the population. The projected duration of
the trial was an average of six years. In March 2000, the
doxazosin arm was terminated on the grounds that it had
become futile to attempt to find a significant difference in
the primary outcome (fatal coronary heart disease or non-
fatal myocardial infarction) by the trial’s scheduled conclu-
sion and, more important, to find it on the basis of a 25%
increase (p , 0.00001) in the secondary end point of
combined cardiovascular events (including heart failure)
among patients treated with doxazosin. Although heart
failure contributed the largest proportion of increased events
in the doxazosin arm of the trial (other components of the
secondary end point included coronary heart disease, stroke,
peripheral vascular disease, vascular procedures, and angina
pectoris), without the heart-failure component, a 13%
increase in the combined end point (p , 0.001) remained.
No difference was observed in the primary end point, or in
total cumulative mortality, between patients treated with
chlorthalidone and those who received doxazosin. The
effects of chlorthalidone and doxazosin on reductions in
systolic and diastolic blood pressure (BP) were largely
similar. It was concluded that chlorthalidone is superior to
doxazosin for the treatment of high-risk hypertensive pa-
tients. Chlorthalidone, and probably diuretics as a class,
should remain the drug therapy of first choice for patients
with hypertension. Alpha-adrenergic blockers are not rec-
ommended as a first-line treatment for hypertension.
Commentary. The ALLHAT study brings forth one of
the most crucial issues in contemporary medicine. Can we
assume that therapies that affect surrogate end points in the
same way will affect clinical outcomes similarly? The answer
is, apparently, “no.” For years, BP has been considered a
straightforward surrogate: there is a direct relationship
between BP reduction and reduction in the risk of stroke in
particular but also a reduction in the coronary heart disease
end points in general. The ALLHAT Study points out that
two agents that lower BP to the same degree may have
different effects on clinical outcomes, leading to the ines-
capable conclusion that, when it is possible, we need to
measure the impact of therapies on tangible human out-
comes (death, events, and quality of life).
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